Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study

INTERVENTION: Intervention group one: Quetiapin 50‐800 mg per day orally over 24 weeks. Intervention group two: Sertralin 25‐200 mg per day orally also over 24 weeks. CONDITION: Borderline Personality Disorder ; Mental and Behavioural Disorders ; Borderline Personality Disorder PRIMARY OUTCOME: The primary assessment instrument will be the Symptom Check List 90 (SCL‐90R) and the primary outcome parameter will be the anger/hostility subscale of the SCL‐90R. SECONDARY OUTCOME: 1. Severity of affective symptoms; 2. Anxiety and depressive symptoms; 3. Psychotic or psychosis‐like symptoms; 4. Interpersonal problems; 5. Duration of hopsitalisation; 6. Co‐medication INCLUSION CRITERIA: 1. Borderline personality disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) 2. At least 18 years of age 3. Voluntary legal basis 4. Female 5. Written informed consent before entering the study 6. No relevant abnormalities in Electrocardiogram (ECG) and laboratory tests